David R. Taft

Cleveland Clinic — United States

Medicine · Health Sciences

19h-index1.3kcitations86works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(20), Pharmacogenetics and Drug Metabolism(10), Pharmacological Effects and Toxicity Studies(10), HIV/AIDS drug development and treatment(8), Antibiotics Pharmacokinetics and Efficacy(7)

Publications86 total

ASO Visual Abstract: Impact of Second Opinions on Time to Treatment of Breast Cancer
Annals of Surgical Oncology·2025
Impact of Second Opinions on Time to Treatment of Breast Cancer
Annals of Surgical Oncology·2025· 2 citedOpen Access
PBPK Modeling of Acetaminophen in Pediatric Populations: Incorporation of SULT Enzyme Ontogeny to Predict Age-Dependent Metabolism and Systemic Exposure
Life·2025Open Access
PBPK Modeling for Enhanced Drug Therapy in the Elderly Population and the Impact of Organ Impairment on Systemic Exposure
Current Pharmacology Reports·2025· 1 cited
Correction to “Inhaled JAK Inhibitor GDC-0214 Nanoaggregate Powder Exhibits Improved Pharmacokinetic Profile in Rats Compared to the Micronized Form: Benefits of Thin Film Freezing”
Molecular Pharmaceutics·2024Open Access
Inhaled JAK Inhibitor GDC-0214 Nanoaggregate Powder Exhibits Improved Pharmacokinetic Profile in Rats Compared to the Micronized Form: Benefits of Thin Film Freezing
Molecular Pharmaceutics·2024· 3 cited
PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population
Pharmaceutics·2023· 2 citedOpen Access
Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole
Pharmaceutics·2023· 9 citedOpen Access
Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma
Blood·2021· 2 cited
Application of Physiologically Based Pharmacokinetic‐Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial Effect
The Journal of Clinical Pharmacology·2021· 13 cited
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Blood·2021· 200 citedOpen Access
Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption
Drug Metabolism and Pharmacokinetics·2020· 8 cited
Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
Blood·2019· 22 cited
Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine
Current Drug Discovery Technologies·2019· 6 cited
Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats
European Journal of Drug Metabolism and Pharmacokinetics·2019· 3 cited
Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine
Blood·2018· 1 cited
Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials
Blood·2018· 3 cited
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
Blood·2018· 7 cited
Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment
Open Forum Infectious Diseases·2018· 25 citedOpen Access
Abstract 4906: Effect of gender on the rodent pharmacokinetics of ON 123300, a dual inhibitor of ARK5 and CDK4/6, for the treatment of cancer
Cancer Research·2018
page 1 of 5Next →

Frequent Co-authors

Manoj Maniar(10), Alex F. Herrera(6), Alison J. Moskowitz(6), Nancy L. Bartlett(6), Julie M. Vose(6), Tatyana Feldman(6), Ann S. LaCasce(6), Stephen M. Ansell(6), Craig H. Moskowitz(6), Ranjana H. Advani(6), Radhakrishnan Ramchandren(5), Chen Ren(5), Keenan Fenton(4), Carol Anne Ogden(4), Robert A. Bellantone(4), Ganesh R. Iyer(4), Kazunobu Kato(3), Mary S. Campbell(3), Beth Christian(3), Mariana Sacchi(3)